Literature DB >> 17322599

A clinicopathological study of eyelid malignancies from central India.

Sameer S Jahagirdar1, Tushar P Thakre, Satish M Kale, Hemant Kulkarni, Manju Mamtani.   

Abstract

BACKGROUND: Eyelid malignancies are completely treatable if detected early. The treatment depends on the invasiveness of the cancer which in turn depends on the type of malignancy. AIM: The aim of the study was to characterize the distribution of the types of eyelid malignancies in central India. SETTINGS AND
DESIGN: The study was conducted in the Department of Plastic and Maxillofacial Surgery at a tertiary care hospital.
MATERIALS AND METHODS: We report a series of 27 cases of eyelid malignancies. In the same case series, we also include a case of malignant hemangiopericytoma which is an extremely rare form of eyelid malignancy worldwide. STATISTICAL ANALYSIS: Depending on the underlying statistical distribution, either analysis of variance (ANOVA) or the Kruskal-Wallis (K-W) test was used to assess the differential distribution of these variables across the types of eyelid malignancies observed in this study.
RESULTS: We observed that sebaceous cell carcinoma (approximately 37%) was almost as prevalent as basal cell carcinoma (approximately 44%) in the study subjects and had an earlier age of occurrence and a more rapid clinical course.
CONCLUSIONS: Sebaceous cell carcinoma of the eyelid is almost as common as basal cell carcinoma in a large tertiary care centre in central India.

Entities:  

Mesh:

Year:  2007        PMID: 17322599     DOI: 10.4103/0301-4738.30703

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


  8 in total

1.  Clinicopathological analysis of eyelid malignancies - A review of 85 cases.

Authors:  Satish M Kale; Surendra B Patil; Nishant Khare; Mahantesh Math; Arvind Jain; Sumeet Jaiswal
Journal:  Indian J Plast Surg       Date:  2012-01

2.  Massive periocular squamous cell carcinoma engulfing the globe: a rare case report.

Authors:  Rajender Singh Arora; Anirudh Bhattacharya; Dwarkadas Adwani; Sidak Singh Arora
Journal:  Case Rep Oncol Med       Date:  2014-07-24

3.  Eyelid sebaceous gland carcinoma: Varied presentations and reconstruction outcome.

Authors:  Syed Ali Raza Rizvi; Md Shahid Alam; Kafil Akhtar
Journal:  Oman J Ophthalmol       Date:  2018 Jan-Apr

4.  Prevalence of Histopathologically Diagnosed Ophthalmic Neoplastic Lesion Among Ophthalmic Biopsies in a Pathology Laboratory of Tertiary Hospital of Nepal.

Authors:  Santosh Upadhyaya Kafle; Mrinalini Singh; Prerna Arjyal Kafle; BalKumar Kc; Sanjeeb Kumar Yadav; Anadi Khatri Kc; Madhav Panthi
Journal:  JNMA J Nepal Med Assoc       Date:  2019 Sep-Oct       Impact factor: 0.406

5.  Clinicopathological Analysis and Surgical Outcome of Eyelid Malignancies: A Study of 332 Cases.

Authors:  Syeed Mehbub Ul Kadir; Mukti Rani Mitra; Riffat Rashid; Murtuza Nuruddin; Md Kamrul Hassan Khan; Golam Haider; Mst Sayedatun Nessa
Journal:  J Skin Cancer       Date:  2022-02-18

6.  The spectrum and clinicopathological correlation of eyelid lesions: Twenty years' experience at a tertiary eye care center in South India.

Authors:  Prabrisha Banerjee; Kirthi Koka; Md Shahid Alam; Nirmala Subramanian; Jyotirmay Biswas; Subramanian Krishnakumar; Bipasha Mukherjee
Journal:  Indian J Ophthalmol       Date:  2022-01       Impact factor: 1.848

7.  Immunohistochemistry on pattern of ocular & adnexal tumours in a tertiary eye care centre of Northeast India.

Authors:  Dipankar Das; Harsha Bhattacharjee; Apurba Deka; Panna Deka; Samir Serasiya; Kasturi Bhattacharjee; Jayanta Kumar Das; Ganesh Chandra Kuri; Eknath Pawar; Rushil Kumar Saxena
Journal:  Indian J Med Res       Date:  2018-01       Impact factor: 2.375

8.  Malignant tumors of the eyelid in India: A multicenter, multizone study on clinicopathologic features and outcomes.

Authors:  Roshmi Gupta; Anirban Bhaduri; Savari Desai; Sima Das; Vikas Menon
Journal:  Indian J Ophthalmol       Date:  2020-11       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.